Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tenax Therapeutics (TENX)

Tenax Therapeutics (TENX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,154
  • Shares Outstanding, K 298
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,050 K
  • 60-Month Beta 2.29
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.10
Trade TENX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -8.15
  • Number of Estimates 2
  • High Estimate -6.96
  • Low Estimate -9.33
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.48 +11.21%
on 03/26/24
5.17 -25.14%
on 03/04/24
-0.31 (-7.42%)
since 02/27/24
3-Month
3.48 +11.21%
on 03/26/24
27.33 -85.84%
on 12/28/23
-19.57 (-83.49%)
since 12/27/23
52-Week
3.48 +11.21%
on 03/26/24
61.20 -93.68%
on 11/14/23
-36.51 (-90.42%)
since 03/27/23

Most Recent Stories

More News
Tenax Therapeutics: Q3 Earnings Snapshot

Tenax Therapeutics: Q3 Earnings Snapshot

TENX : 3.87 (+4.31%)
Tenax Therapeutics (NASDAQ: TENX) Granted U.S. Patent for IV Levosimendan for Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics, Inc. (NASDAQ: TENX) is engaged as a specialty pharmaceutical company, which is focused on the research, development and

TENX : 3.87 (+4.31%)
Stocks Set To Open Higher As Dovish Powell Comments Boost Sentiment, ECB Decision In Focus

March S&P 500 futures (ESH23) are trending up +0.47% this morning after three major U.S. benchmark indices staged a rebound on Wednesday after the Federal Reserve announced a further slowdown in the pace...

ESH23 : 3,957.05s (-0.09%)
META : 493.86 (-0.41%)
AAPL : 173.31 (+2.12%)
GOOG : 151.94 (+0.16%)
AMZN : 179.83 (+0.86%)
MRK : 131.75 (+4.96%)
COP : 126.84 (+0.67%)
F : 13.06 (+4.98%)
SHEL.LN : 2,621.085 (+0.31%)
TENX : 3.87 (+4.31%)
ALGN : 327.90 (+2.49%)
ELF : 196.25 (-0.79%)
Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH)

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high...

TENX : 3.87 (+4.31%)
Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...

TENX : 3.87 (+4.31%)
Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...

TENX : 3.87 (+4.31%)
Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...

TENX : 3.87 (+4.31%)
Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...

TENX : 3.87 (+4.31%)
Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors

MORRISVILLE, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying,...

TENX : 3.87 (+4.31%)
Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102)

Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjects with Any Health Condition Patent Term to 2039, Exclusive of Any Possible...

TENX : 3.87 (+4.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The Company specializes in creating pharmaceuticals and medical devices in the fields of oxygen therapeutics, blood substitutes, and liquid ventilation...

See More

Key Turning Points

3rd Resistance Point 4.36
2nd Resistance Point 4.15
1st Resistance Point 4.01
Last Price 3.87
1st Support Level 3.66
2nd Support Level 3.46
3rd Support Level 3.32

See More

52-Week High 61.20
Fibonacci 61.8% 39.15
Fibonacci 50% 32.34
Fibonacci 38.2% 25.53
Last Price 3.87
52-Week Low 3.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar